Richard E Wendell

Address:

511 Old Ml Rd, Pittsburgh, PA 15238

Phone:

(412)9636986

VIN:

WBAWB73527PV80841

Make:

BMW

Model:

3 SERIES

Year:

2007

US Patent:

49476866, Aug 14, 1990

Filed:

Mar 6, 1989

Appl. No.:

7/319656

Inventors:

Richard H. Wendell - Golden CO
Tracy J. Fowler - Denver CO

Assignee:

Adolph Coors Company - Golden CO

International Classification:

G01L 504

US Classification:

73159

Abstract:

An apparatus for use in determining the approximate web tension setting necessary for providing a predetermined web width in a machine, such as a web printer, which is used to process a continuous plastic web of the type which is subject to significant stretching and shrinking in response to relatively small web tension variations, comprising a first web restraining device for holdingly engaging a first end of a length of web material to be tested; a second web restraining device for holdingly engaging a second end of the length of web material to be tested; a force application device for applying a controlled amount of longitudinal stretching force to the length of web material to be tested; and a measuring device for measuring the width of the length of web material to be tested in a mid-region thereof during application of the longitudinal stretching force thereto. The apparatus may also be used for determining web graphics distortion.

US Patent:

20190080057, Mar 14, 2019

Filed:

Sep 12, 2018

Appl. No.:

16/129551

Inventors:

Michael STANLEY - New York NY, US
Eric TANALSKI - New York NY, US
Peter TERLECKY - New York NY, US
Richard WENDELL - New York NY, US

International Classification:

G06K 9/62

Abstract:

A system of generating a suitability and/or toxicity score for a compound of interest is described. The system may be trained by obtaining physical properties of compounds; retrieving or predicting physiological binding sites or targets of the compound; and using clinical data for known compounds and interactions. Suitability or toxicity for a compound of interest may be obtained based upon a machine-learning prediction. In such a system, the clinical descriptions for the compound may include at least one of an indication for use of the compound and a therapeutic area of the compound, and also may include the use of gene expression strength metrics.